Clinical observation of Shengxuening combined with erythropoietin in treatment of renal anemia

Objective To investigate the effect of Shengxuening combined with erythropoietin in the treatment of renal anemia. Methods A randomised, controlled and clinical research was conducted. A total of 60 chronic kidney disease inpatients with renal anemia was divided into two groups, and 30 inpatients for each group. Treatment group were treated with erythropoietin (EPO) and 0.5 g of Shengxuening tablet orally, three times each day. Control group were treated with only EPO. The course of treatment was 12 weeks. The initial dosage of EPO was 150 U/(kg·weeks). When the levels of hemoglobin ≥ 130 g/L, hct 33%, and the dosage of EPO was gradually tapered to a maintenance dose. Results Before the treatment, there were no significant differences in erythrocyte count, levels of hemoglobin, serum ferritin and transferrin saturation between the two groups (P 0.05). After the treatment, the levels of hemoglobin, RBC, SF and TAST in both groups were improved, all P 0.05. Compared with control group, the treatment group had significant higher levels of Hb, RBC, SF and TAST (all P 0.05). The effective rate was 83.3% in the treatment group and 70.0% in the control group; the total effective rate was 96.7% in the treatment group and 90.0% in the control group. And the maintaining dosages of EPO in the treatment group was lower than the control group. Conclusion Shengxuening tablet is effective for the treatment of renal anemia. Shengxuening tablet might improve the sensitive of EPO, contribute to the lower maintaining dosages of EPO.